Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 68INDUSTRY 15OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Metastatic Gastroesophageal Junction Adenocarcinoma 1

Interventions

Capecitabine 9Bevacizumab 8tislelizumab 7Oxaliplatin 7Drug Therapy 7pembrolizumab 6Surgical Procedures, Operative 6Cisplatin 6Standard of Care 5Radiotherapy 5Laparoscopy 5Fluorouracil 5Docetaxel 5Carboplatin 5toripalimab 4Radiosurgery 4Leucovorin 4Exercise 4Epirubicin 4Cyclophosphamide 4pertuzumab 3durvalumab 3dalpiciclib 3atezolizumab 3anlotinib 3Saline Solution 3Rituximab 3Radiation 3Prednisone 3Population Groups 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × sintilimab × 1 year × Clear all
NCT05177068 2025-10-02

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Henan Cancer Hospital

Phase 2 Active not recruiting
42 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06329973 2025-07-17

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Henan Cancer Hospital

Phase 1/2 Recruiting
70 enrolled
Gastrointestinal

Metastatic Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡